FTI vs RCUS
TechnipFMC plc vs Arcus Biosciences, Inc. — Side-by-Side Stock Comparison
FTI
TechnipFMC plc
8.5
Strong Buy
$69.81
RCUS
Arcus Biosciences, Inc.
4.9
Weak
$21.87
FTI vs RCUS: Which is the Better Investment?
TechnipFMC plc (FTI) scores 8.5/10 while Arcus Biosciences, Inc. (RCUS) scores 4.9/10 on AlphaStocks' composite model. TechnipFMC plc has the higher composite rating of Strong Buy.
This comparison is algorithmically generated and is not financial advice.
| Metric | FTI | RCUS |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 8.5/10▲ | 4.9/10 |
| Rating | Strong Buy▲ | Weak |
| Price | $69.81 | $21.87 |
| P/E Ratio | 30.4 | — |
| ROE | 28.8%▲ | -18.0% |
| Market Cap | $29B | $2B |
| Fair Value | $48.94 | — |
| Dividend Yield | — | — |
| Sector Rank | #2 of 1127▲ | #605 of 1127 |
| Model Verdicts | ||
| Piotroski | Strong▲ | Caution |
| Buffett | Strong▲ | Caution |
| Graham | Caution | Neutral▲ |
| Lynch | Strong▲ | Limited Data |
| Greenblatt | Neutral▲ | Caution |
FTI vs RCUS: Which Stock Scores Higher?
TechnipFMC plc (FTI) and Arcus Biosciences, Inc. (RCUS) are among the most compared stocks in the S&P 500. FTI currently leads with a composite score of 8.5/10 (Strong Buy) compared to RCUS's 4.9/10 (Weak).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer